Effect of estrogens on bone and other systems and hormonal substitute treatment

Current Opinion in Rheumatology

Volumn 9, Issue 4, 1997, Pages 362-369

  Ribot, Claude A ^a   Trémollieres, Florence A ^a  

^a CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTROGEN; ESTROGEN RECEPTOR; HORMONE; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; BONE; BONE CELL; BONE MARROW; BREAST CANCER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; ESTROGEN THERAPY; FEMALE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; MENOPAUSE; ONSET AGE; OSTEOCLAST; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK; RISK BENEFIT ANALYSIS;

BONE AND BONES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS;

EID: 0030797695     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199707000-00015     Document Type: Review

References (82)

1. Albright F, Smith PH, Richardson AM: Postmenopausal osteoporosis. JAMA 1941, 116:2465-2474.
2. Pilbeam CC, Klein-Nulend J, Raisz LG: Inhibition by 17β-estradiol of PTH stimulated resorption and prostaglandin production in cultured neonatal mouse calvariae. Biochem Biophys Res Commun 1989, 163:1319-1324.
3. Fukayam S, Tashjian AH: Direct modulation by estradiol of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related peptide. Endocrinology 1989, 124:397-401.
4. Navey-Many T, Almogi G, Livni N, Silver J: Estrogen receptors and biologic response in rat parathyroid tissue and C cells. J Clin Invest 1992, 90:2434-2438.
5. Marcus R: Estrogens and progestins in the management of primary hyperparathyroidism. J Bone Miner Res 1991, 6:S125-S129.
6. McKane WR, Khosla S, Burrit MF, Kao PC, Wilson DM, Ory SJ, Riggs BL: Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmenopause: a clinical research center study. J Clin Endocrinol Metab 1995, 80:3458-3464.
7. Greenberg C, Kukreja C, Bowser N, Hargis GK, Henerson WJ, Williams GA: Effects of estradiol and progesterone on calcitonin secretion. Endocrinology 1986, 118:2594-2598.
8. Ishibe M, Nojima T, Ishibashi T, Koda T, Kaneda K, Rosier RN, Puzas JE: 17 beta-estradiol increases the receptor number and modulates the action of 1,25-dihydroxyvitamin D-3 in human osteosarcoma-derived osteoblast-like cells. Calcif Tissue Int 1995, 57:430-435.
9. Komm BS, Terpening C, Benz DJ, Graeme KA, Gallegos A, Korc M, Greene GL, O'Malley BW, Haussler MR: Estrogen binding, receptor mRNA and biologic response in osteoblast-like osteosarcoma cells. Science 1988, 241:81-83.
10. Eriksen EF, Colvard DS, Berg NJ, Graham ML, Mann KG, Spelsberg TC, Riggs BL: Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988, 241:84-86.
11. Lubahn DB, Moyer JS, Golding TS, Couse JF, Korach KS, Smithies O: Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci U S A 1993, 90:1162-1166.
12. Smith EP, Boyd J, Franck GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS: Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994, 331:1056-1061.
13. Hoshino S, Inoue S, Hosoi T, Saito T, Ikegami M, Ouchi Y, Orimo H: Demonstration of isoforms of the estrogen receptor in the bone tissues and in osteoblastic cells. Calcif Tissue Int 1995, 57:466-468.
14. Etienne MC, Fischel JL, Milano G, Formento P, Formento JL, Francoual M, Frenay M, Namer M: Steroid receptors in human osteoblast-like cells. Eur J Cancer 1990, 28:807-810.
15. MacNamara P, Oshaughnessy C, Manduca P, Loughrey HC: Progesterone receptors are expressed in human osteoblast-like cell lines and in primary human osteoblast cultures. Calcif Tissue Int 1995, 57:436-441.
16. Colvard DS, Eriksen EF, Keeting PE, Wilson EM, Lubahn DB, French FS, Riggs BL, Spelsberg TC: Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci U S A 1989, 86:854-857.
17. Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russel RGG: An interleukin-1-like factor stimulates bone resorption in vitro. Nature 1983, 306:378-380.
18. Thomson BM, Mundy GR, Chambers TJ: Tumor necrosis factors α and β induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987, 138:775-779.
19. Pfeilschifter J, Chenu P, Bird A, Mundy GR, Roodman GD: Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclast-like cells in vitro. J Bone Miner Res 1989, 4:113-118.
20. Suda T, Takahashi N, Martin TJ: Modulation of osteoclast differentiation. Endocrine Rev 1992, 13:66-80.
21. Lowik CWGM, Van der Plujim G, Bloys H, Hoekeman K, Bijvoet OLM, Aarden LA, Papapoulos SE: Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate IL-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 1993, 162:1546-1552.
22. Girasole G, Jilka RL, Passeri G, Boswell S, Boder G, Williams DC, Manolagas SC: 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992, 89:883-891.
23. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas SC: Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257:88-91.
24. Pacifici R, Rifas L, Teitelbaum S, Slatopolsky E, McCracken R, Bergfeld M, Lee W, Avioli LV, Peck WA: Spontaneous release of interleukin-1 from human blood monocytes reflects bone formation in idiopathic osteoporosis. Proc Natl Acad Sci U S A 1987, 84:4616-4620.
25. Pacifici R, Brown C, Puschek E, Friedrich E, Slatopolsky E, Maggio D, McCracken R, Avioli LV: Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A 1991, 88:5134-5138.
26. Cohen-Solal ME, Graulet AM, Denne MA, Guerris J, Bayling DJ, De Vernejoul MC: Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab 1993, 77:1648-1653.
27. Bismar H, Diel I, Ziegler R, Pfeilschifter J: Increased cytokine secretion by human marrow cell after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995, 80:3351-3355.
28. Kassem M, Khosla S, Spelsberg TC, Riggs BL: Cytokine production in the bone marrow microenvironment: failure to demonstrate estrogen regulation in early postmenopausal women. J Clin Endocrinol Metab 1996, 81:513-518.
29. Oursler MJ, Cortese C, Keeting P, Anderson MA, Bonde SK, Riggs BL, Speisberg TC: Modulation of transforming growth factor-beta production in normal human osteoblast-like cells by 17 beta-estradiol and parathyroid hormone. Endocrinology 1991, 129:3313-3320.
30. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF: Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nature Med 1996, 2:1132-1136. This is the first demonstration that estrogen increases osteoclast apoptosis in vitro and in vivo and that this effect is likely to be mediated by increased production of TGF-β. This study also shows that tamoxifen, which acts as a weak agonist in bone, had effects similar to those of 17β-estradiol on osteoclast apoptosis.
31. Yang NN, Venugopalan M, Hardikar S, Glasebrook A: Identification of an estrogen response element activated by metabolites of 17β-estradiol and raloxifene. Science 1996, 273:1222-1225. This study explores the pathways for the modulation of gene transcription by metabolites of 17β-estradiol and raloxifene (an estrogen analog). In osteosarcoma cells, raloxifene was more likely to activate the TGFβ3 gene than was 17β-estradiol. This activation, which required the estrogen receptor, was not dependent on the DNA binding domain of the estrogen receptor. The authors identified a specific sequence, called raloxifene response element, which was necessary for gene activation. The modulation of multiple DNA response elements may explain the tissue-selective agonist or antagonist activity of estrogen analogs.
32. Ribot C, Trémollieres F, Pouilles JM: Prevention of postmenopausal bone loss by long-term patenteral administration of 17β estradiol: comparison of percutaneous and transdermal route. In Osteoporosis: Physiological Basis, Assessment and Treatment. Edited by DeLuca H, Mazess R. New York: Elsevier Science Publishing; 1989:137-145.
33. Reginster JY, Sarlet N, Deroisy R, Albert A, Gaspard U, Franchimont P: Minimal levels of serum estradiol prevent postmenopausal bone loss. Calcif Tissue Int 1992, 51:340-343.
34. Riis BJ, Thomsen K, Strom V, Christiansen C: The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987, 156:61-64.
35. Gallagher JC, Kable WT: Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991, 90:171-178.
36. Ribot C, Trémollieres F, Pouilles JM: Traitement hormonal et prévention de l'ostéoporose post-ménopausique: analyse critique. In Evaluation des Traitements de la Ménopause. Edited by Caulin C, Chastang C, Kuntz D. Paris: Springer-Verlag; 1992:61-71.
37. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR: Estrogen replacement therapy in older women. Arch Intern Med 1995, 122:9-16. This prospective cohort study of 9704 white women 65 years of age or older demonstrated that current estrogen use is associated with a decrease in the risk for all nonspinal fractures. Estrogen was found to be most effective in preventing hip fracture among those older than 75 years of age. When ERT was started after 5 years of menopause, even long-term users had no significant reduction in the risk for all nonspinal fractures. These results suggest that ERT should be initiated soon after menopause and continued indefinitely.
38. Baudoin C, Fardellone P, Thelot B, Juvin R, Potard V, Bean K, Sebert JL: Hip fractures in France: the magnitude and perspective of the problem. Osteoporosis Int 1996, 6:S1-S10.
39. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ: The effect of postmenopausal estrogen therapy on bone density in elderly women. New Engl J Med 1993, 329:1141-1146.
40. Kanis JA, Johnell O, Gulberg B, Allander E, Dilsen G, Gennari C, Lopez Vaz AA, Lyritis GP, Mazzuoli G, Miravet L, Passeri M, Perez Cano R, Rapado A, Ribot C: Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. Br Med J 1992, 305:1124-1128.
41. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent diseases and prolong life in postmenopausal women. Ann Intern Med 1992, 117:1016-1037.
42. Tunstall-Pedoe H, Kuuslasmaa K, Amouyel P: Myocardial infarction and coronary deaths in the World Health Organization-MONICA project. Circulation 1994, 90:583-612.
43. Wilson PW, Garrison RJ, Castelli WP: Postmenopausal estrogen use, cigarette smoking and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Mad 1985, 313:1038-1043.
44. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 1995, 273:199-208. This first double-blind, placebo-controlled study performed in a large population over 3 years demonstrates the beneficial effect of various estrogen/progestin regimens on lipid profiles and fibrinogen levels. The addition of progestin did not alter estrogen's beneficial effect of lipid profiles.
45. Mendelsohn ME, Karas RH: Estrogen and the blood vessel wall. Curr Opin Cardiol 1994, 9:619-626.
46. Adams MR, Kaplan JR, Manuck SB: Inhibition of coronary artery atherosclerosis by 17β estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Arteriosclerosis 1990, 10:151-157.
47. Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA: Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988, 115:954-963.
48. Sullivan JM, Vander Zwaag R, Lemp G, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM: Postmenopausal estrogen use and coronary artherosclerosis. Ann Intern Med 1988, 108:358-363.
49. MacFarlan KF, Boniface ME, Hornung CA, Earnhardt W, Humphries JON: Risk factors and noncontraceptive estrogen use in women with and without coronary disease. Am Heart J 1989, 117:1209-1214.
50. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM: Estrogen replacement and coronary artery disease: effect on survival in postmenopausal women. Arch Intern Med 1990, 150:2557-2562.
51. Petiti DB, Perlman JA, Sidney S: Noncontraceptive estrogens and mortality: long term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987, 70:289-293.
52. Henderson BE, Paganini-Hill A, Ross RK: Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991, 151:75-78.
53. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC: Decreased risk of stroke among postmenopausal hormone users: results from a national cohort. Arch Intern Med 1993, 153:73-79.
54. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996, 348:977-980.
55. Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogen. Lancet 1996, 348:981-983.
56. Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996, 348:983-987.
57. Toran-Allerand CD, Miranda RC, Bentham WD: Estrogen receptors colocalize, with low affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A 1992, 89:4668-4672.
58. Roselli CE, Horton LE, Resko JA: Distribution and regulation of aromatase activity in the rat hypothalamus and limbic system. Endocrinology 1985, 117:2471-2477.
59. Paganini-Hill A, Henderson VW: Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol 1994, 140:256-261.
60. Brenner DE, Kukull WA, Stergachis A, Van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB: Postmenopausal estrogen replacement therapy and the risk of Alzheimer's disease: a population based case-control study. Am J Epidemiol 1994, 140:262-267.
61. Tang MX, Jacobs D, Stern Y, Marder K, Schofiel P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996, 348:429-432. This population-based study performed in elderly women shows that the relative risk of Alzheimer's disease was significantly reduced (by 60%) among estrogen users compared with nonusers. The age of onset of the disease was significantly later in women who had taken estrogen than in those who had not. Estrogen use in postmenopausal women might thus delay the onset and decrease the risk of Alzheimer's disease.
62. Sherwin BB, Tulandi T: "Add-back" estrogen reverses cognitive deficits induced by a gonadotropin-releasing hormone agonist in women with leiomyomata uteri. J Clin Endocrinol Metab 1996, 81:2545-2549.
63. Schneider LS, Farlow MR, Henderson VW, Pogoda JM: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology 1996, 46:1580-1584.
64. Sohrabji F, Miranda RC, Toran-Allard CD: Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994, 14:459-471.
65. Singh M, Meyer EM, Simpkins JW: The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. Endocrinology 1995, 136:2320-2324.
66. Goodman Y, Bruce AJ, Cheng B, Mattson MP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury and amyloid β-peptide toxicity of hippocampal neurons. J Neurochem 1996, 66:1836-1844.
67. Ohkura T, Teshima Y, Isse K, Matsuda H, Inoue T, Sakai Y, Iwazaki N, Yaoi Y: Estrogen increases cerebral and cerebellar blood flow in post-menopausal women. Menopause 1995, 2:13-18.
68. Luine V, Park F, Joh T: Immunochemical demonstration of increased choline acetyltransferase concentration in rat preoptic area after estradiol administration. Brain Res 1980, 191:273-277.
69. Luine VN: Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas in female rats. Exp Neurol 1985, 89:484-490.
70. Singh M, Meyer EM, Millard WJ, Simpkins JW: Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats. Brain Res 1994, 644:305-312.
71. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE: Estrogen regulates metabolism of Alzheimer's amyloid beta precursor protein. J Biol Chem 1994, 269:13065-13068.
72. Roses AD, Strittmatter WJ, Pericak-Vance MA, Corder EH, Saunders AM, Schmechel DE: Clinical application of apolipoprotein E genotyping to Alzheimer's disease. Lancet 1994, 343:1564-1565.
73. Duara R, Barker WW, Lopez-Alberola R, Loewenstein DA, Grau LB, Gilchrist D, Sevush S, St George-Hystop PH: Alzheimer's disease: interaction of apolipoprotein E genotype, family history of dementia, gender, education, ethnicity and age of onset. Neurology 1996, 46:1575-1579.
74. Honjo H, Tanaka K, Kashiwagi T, Urabe M, Okada H, Hayashi M, Hayashi K: Senile dementia-Alzheimer's type and estrogen. Hormone Metab Res 1995, 27:204-207.
75. Buring JE, Bain CJ, Ehrmann RL: Conjugated estrogen and risk of endometrial cancer. Am J Epidemiol 1986, 124:434-441.
76. Paganini-Hill A, Ross R, Henderson B: Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 1989, 59:445-447.
77. Voigr LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G: Progestogen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991, 338:274-277.
78. Woodruff J, Pickar J: Incidence of endometrial hyperplasia in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Am J Obstet Gynecol 1994, 170:1213-1223.
79. Colditz GA, Hankinson SE, Hunter DJ, Willet WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med 1995, 332:1589-1593.
80. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA: Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995, 274:137-142.
81. Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W, Potter JD: Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995, 85:1128-1132.
82. Ray NF, Chan JK, Thamer M, Melton LJ III: Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:24-35.